
Key Points
- 01Moderna (MRNA) raised its 2026 revenue growth forecast to 15%–25%.
- 02Management now expects about 10 percentage points of gross margin expansion in 2026.
- 03Year-end 2026 liquidity is projected at around $9 billion.
- 04Intismeran plus KEYTRUDA cut melanoma recurrence or death risk by 42% in Phase 3.
Moderna raises 2026 growth guidance
Moderna has increased its 2026 revenue growth outlook to a range of 15% to 25%, revising its previous framework that had targeted growth of up to 10%. Management links the higher projection to stronger demand, improved execution, shipment timing, uptake of its COVID vaccine and partnerships in the United Kingdom, Canada and Australia. The company also expects 2026 revenue to be supported by both U.S. and international markets, with guidance calling for an approximately even split between domestic and overseas sales in that year.
Alongside the stronger revenue outlook, Moderna is targeting approximately 10 percentage points of gross margin expansion in 2026, excluding the impact of a litigation settlement charge. Cost reductions have allowed the company to bring its previously announced 2027 cash cost framework forward into 2026, reinforcing the margin objective. These changes form part of an updated multi-year financial framework presented as Moderna outlines its next phase of growth.
Updated financial framework and liquidity plans
Moderna anticipates ending 2026 with approximately $9 billion in total liquidity, including cash, investments and undrawn borrowing capacity. Within this, the company projects year-end 2026 cash and investments of $8.1 billion to $8.3 billion. The financial outlook is supported by reduced cash costs, which fell 10% year over year in the most recent quarter, and by an increased cash balance of $8 billion at quarter-end compared with $6.9 billion three months earlier.
The company’s financial planning also includes projections for key operating expenses in 2026. Management expects cost of sales of $1.7 billion, research and development expenses of $2.7 billion, selling, general and administrative costs of about $1 billion and capital spending of $200 million. Amendments to a credit facility with Ares have extended its maturity by one year to 2031, reduced drawn interest by 75 basis points and extended the availability of a remaining $900 million borrowing capacity through 2029.
Oncology progress led by intismeran melanoma data
Moderna is coupling its financial guidance with updates on its oncology pipeline, highlighted by Phase 3 results for its individualized cancer treatment intismeran in melanoma. In combination with KEYTRUDA, intismeran reduced the risk of recurrence or death by 42% compared with KEYTRUDA alone in adjuvant melanoma testing. The regimen also reduced the risk of distant metastasis or death by 38% versus KEYTRUDA alone, while meeting primary recurrence-free survival and key secondary distant metastasis-free survival endpoints.
The melanoma data support plans for a biologics license application for intismeran, which Moderna is working on in collaboration with Merck. Beyond intismeran, the company is advancing additional oncology modalities, including cancer antigen therapies, T-cell engagers and cell-therapy enhancement programs. Its mRNA-2.8K multiple myeloma program has been selected for an oral presentation at an upcoming hematology meeting, and the mRNA-2808 multiple myeloma study has shown responses in 4 of 11 heavily pretreated patients in early-stage testing.
Broader pipeline and upcoming milestones
Moderna reports that its mRNA-4359 program is progressing in Phase 2 studies for melanoma and non-small cell lung cancer, adding to its oncology portfolio. The company also notes that its mRNA-3927 program, targeting propionic acidemia, has accumulated more than 50 cumulative patient-years of treatment exposure, with a registrational study readout expected in late 2026. These developments sit alongside commercial plans for respiratory products, including broader launch preparations for its mFLUSIVA vaccine in the 2027–2028 respiratory season.
mFLUSIVA received approvals in the United States and Canada in 2026, and an initial limited U.S. rollout delivered more than 110,000 vaccinations. Together, the updated revenue guidance, margin expansion goals, liquidity plans and advancing clinical programs present a coordinated picture of Moderna’s strategy for growth through 2026 and beyond.
Key Takeaways
- 01Moderna (MRNA)’s upgraded 2026 revenue growth range to 15%–25% is backed by both commercial performance and expanded geographic reach.
- 02Projected margin expansion and detailed cost targets show management focusing on profitability alongside top-line growth.
- 03Progress in melanoma and other oncology programs positions cancer treatments as an increasingly central driver of Moderna (MRNA)’s long-term strategy.
References
- https://investorshub.advfn.com/market-news/article/39899/moderna-raises-2026-revenue-growth-forecast-to-15-25-and-reports-progress-in-cancer-vaccine-development?.tsrc=rss
- https://www.stocktitan.net/news/MRNA/moderna-outlines-next-phase-of-growth-at-analyst-h470biqs2x4t.html
- https://www.tipranks.com/news/company-announcements/moderna-earnings-call-signals-growth-and-oncology-momentum